MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...
Milestone Pharma (MIST) stays a Hold after Q1 misses and a tough CARDAMYST launch; PSVT pricing, uptake, and payer risk loom.
Atrial fibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heart failure. It's the most common type of arrhythmia, a potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results